One patient with two deleterious PALB2 mutations, one in exon 4, c.1653T>A, and another in exon 6, c.2576C>G, was administered with olaparib and showed a 70% reduction in the tumor burden [47]. This evidence concerns the gene PALB2 and neoplasm.